Patents by Inventor Jason Benjamin Bock

Jason Benjamin Bock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia
    Publication number: 20150202268
    Abstract: Disclosed are compositions and methods for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count. The methods and compositions described herein include a fusion polypeptide formed from human serum albumin protein (“HSA”) and human granulocyte-colony stimulating factor (“G-CSF”).
    Type: Application
    Filed: December 18, 2014
    Publication date: July 23, 2015
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Jason Benjamin BOCK, Adam Carr BELL, Jeffery HERPST
  • Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor
    Patent number: 8993519
    Abstract: Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: March 31, 2015
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Jason Benjamin Bock, Xia Luo
  • Stable formulations of highly concentrated recombinant human albumin-human granulocyte colony stimulating factor
    Patent number: 8323634
    Abstract: Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: December 4, 2012
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Jason Benjamin Bock, Xia Luo
  • Stable Formulations Of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor
    Publication number: 20100297062
    Abstract: Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.
    Type: Application
    Filed: January 15, 2010
    Publication date: November 25, 2010
    Inventors: Jason Benjamin Bock, Xia Luo
  • Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor For The Prevention Of Neutropenia
    Publication number: 20100227818
    Abstract: Disclosed are compositions and methods for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count. The methods and compositions described herein include a fusion polypeptide formed from human serum albumin protein (“HSA”) and human granulocyte-colony stimulating factor (“G-CSF”).
    Type: Application
    Filed: January 15, 2010
    Publication date: September 9, 2010
    Inventors: Jason Benjamin Bock, Adam Carr Bell, Jeffrey Herpst